| 翻訳と辞書 |
| Panobinostat ： ウィキペディア英語版 |
Panobinostat
Panobinostat (LBH-589, trade name Farydak) is a drug developed by Novartis for the treatment of various cancers. It is a hydroxamic acid〔 and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).〔(Table 3: Select epigenetic inhibitors in various stages of development ) from 〕
On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma who had received at least 2 previous treatments, including bortezomib and an immunomodulatory agent."〔(FDA.gov announcement about accelerated approval of panobinostat (Farydak) )〕 after clinical trials.〔(Panobinostat chemotherapy regimen for multiple myeloma (MM wiki) )〕
==Clinical trials==
, it is being tested against Hodgkin's Lymphoma, cutaneous T cell lymphoma (CTCL) and other types of malignant disease in Phase III clinical trials, against myelodysplastic syndromes, breast cancer and prostate cancer in Phase II trials, and against chronic myelomonocytic leukemia (CMML) in a Phase I trial.〔(ClinicalTrials.gov: LBH-589 )〕
Panobinostat is being used in a Phase I/II clinical trial that aims at curing AIDS in patients on highly active antiretroviral therapy (HAART). In this technique, panobinostat is used to drive the HIV DNA out of the patient's DNA, in the expectation that the patient's immune system in combination with HAART will destroy it.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Panobinostat」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|